Medically reviewed by Jane Kim, MD Key Takeaways Mounjaro is the first dual GIP and GLP-1 agonist medication approved for ...

Versatile Application: The therapy shows promise for both Type 1 and Type 2 diabetes, as well as diabetes-related complications The lead author of the review, Dr. Jonathan RT Lakey, PhD, MSM, ...

SAN DIEGO--(BUSINESS WIRE)--Global Institute of Stem Cell Therapy and Research, Inc. known as GIOSTAR, a San Diego, California based Global organization at the forefront of stem cell research over two ...

SAN DIEGO, CA—The Global Institute of Stem Cell Therapy and Research (GIOSTAR), based here which is focused on developing innovative therapies to improve the care of patients with Type II diabetes has ...

These factors prompted research into better and more permanent treatments for T1D. The most obvious solution: restore the natural repertoire of β cell islets. Although most recipients experienced ...

Over the last two and a half decades, advancements in stem cell biology and immunology have improved the potential for cell therapy as a treatment for diabetes. Stem cells from different sources can ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

The cure for diabetes is a life free from daily insulin injections. Based on that criterion, ten out of 12 people (83%) in a new clinical trial were cured of their diabetes one year after receiving an ...

Diabetes mellitus is one of the leading public health concerns in the United States. In 2021, approximately 38.4 million people of all ages were living with diabetes, about 11.6 percent of the total U ...

Explore scalable strategies for iPSC-derived islet differentiation using GMP-grade activin A and KGF to advance diabetes ...